Blab Business
Dennis Cho Sells 14,205 Twist Bioscience Shares in Largest Insider Sale of 2026
On May 29, 2026, Twist Bioscience’s chief legal officer, Dennis Cho, made headlines by liquidating nearly a quarter‑million dollars of the company’s stock. In a Form 4 filed with the U.S. Securities and Exchange Commission, Cho reported selling 14,205 shares of Twist’s common stock for approximately $991,000. The trade cut his direct holdings from 134,299 to 120,094 shares.
The 14,205‑share disposition is the largest single sale Cho has executed in the past two years. The filing lists 54 sell‑only trades during that period, with an average size of 1,147 shares. Thus, the May 29 transaction is almost 12 times larger than his typical sell‑only trade and represents 10.58 % of his direct holdings at the time.
Twist’s share price closed at $66.87 on the day of the sale, a 131.5 % jump from the price one year earlier. At the close, the company’s market capitalization stood at $4.31 billion, trailing‑12‑month revenue was $409.48 million, and it posted a net loss of $81.28 million. Cho’s remaining 120,094 shares now account for roughly 0.19 % of the company’s outstanding shares.
Founded in 2013, Twist Bioscience specializes in high‑throughput synthetic DNA manufacturing using a proprietary silicon‑based platform. Its customers include pharmaceutical and biotechnology firms, academic researchers, and diagnostic companies. The company generates revenue from the sale of synthetic DNA products and from collaborative research agreements.
The transaction was executed at $69.75 per share, the price reported in the Form 4. The aggregate value of $991,000 reflects the 14,205 shares sold at that price. The filing also notes that Cho’s post‑transaction holdings are valued at $8.03 million, calculated using the May 29 closing price.
From a regulatory standpoint, the disclosure complies with the Securities Exchange Act of 1934, which requires insiders to file Form 4 within two business days of a trade. The filing does not indicate any conflict of interest or violation of corporate policy, nor does it provide any commentary on the company’s future prospects or on the reasons for Cho’s sale.
Investors may interpret the sale as a liquidity event for Cho rather than a signal of company performance. The fact that the trade occurred after a period of significant share‑price appreciation could suggest that Cho chose to realize gains, but the filing contains no statement from Cho or the company explaining the motivation.
As of the filing date, Twist Bioscience had no announced changes to its executive team or board of directors, and the company has not issued any press release or other communication about the sale. The next quarterly earnings report is scheduled for the end of the third quarter of 2026, at which time the company will provide updated financial results and guidance.
In summary, Dennis Cho’s May 29, 2026 sale of 14,205 Twist Bioscience shares represents the largest insider disposition in the past two years, a 12‑fold increase over his average sell‑only trade size, and a 10.58 % reduction in his direct holdings. The transaction occurred during a period of strong share‑price performance, and the company remains unchanged in terms of leadership or strategy. Investors will likely monitor the upcoming earnings release for further insight into Twist Bioscience’s financial trajectory.
The 14,205‑share disposition is the largest single sale Cho has executed in the past two years. The filing lists 54 sell‑only trades during that period, with an average size of 1,147 shares. Thus, the May 29 transaction is almost 12 times larger than his typical sell‑only trade and represents 10.58 % of his direct holdings at the time.
Twist’s share price closed at $66.87 on the day of the sale, a 131.5 % jump from the price one year earlier. At the close, the company’s market capitalization stood at $4.31 billion, trailing‑12‑month revenue was $409.48 million, and it posted a net loss of $81.28 million. Cho’s remaining 120,094 shares now account for roughly 0.19 % of the company’s outstanding shares.
Founded in 2013, Twist Bioscience specializes in high‑throughput synthetic DNA manufacturing using a proprietary silicon‑based platform. Its customers include pharmaceutical and biotechnology firms, academic researchers, and diagnostic companies. The company generates revenue from the sale of synthetic DNA products and from collaborative research agreements.
The transaction was executed at $69.75 per share, the price reported in the Form 4. The aggregate value of $991,000 reflects the 14,205 shares sold at that price. The filing also notes that Cho’s post‑transaction holdings are valued at $8.03 million, calculated using the May 29 closing price.
From a regulatory standpoint, the disclosure complies with the Securities Exchange Act of 1934, which requires insiders to file Form 4 within two business days of a trade. The filing does not indicate any conflict of interest or violation of corporate policy, nor does it provide any commentary on the company’s future prospects or on the reasons for Cho’s sale.
Investors may interpret the sale as a liquidity event for Cho rather than a signal of company performance. The fact that the trade occurred after a period of significant share‑price appreciation could suggest that Cho chose to realize gains, but the filing contains no statement from Cho or the company explaining the motivation.
As of the filing date, Twist Bioscience had no announced changes to its executive team or board of directors, and the company has not issued any press release or other communication about the sale. The next quarterly earnings report is scheduled for the end of the third quarter of 2026, at which time the company will provide updated financial results and guidance.
In summary, Dennis Cho’s May 29, 2026 sale of 14,205 Twist Bioscience shares represents the largest insider disposition in the past two years, a 12‑fold increase over his average sell‑only trade size, and a 10.58 % reduction in his direct holdings. The transaction occurred during a period of strong share‑price performance, and the company remains unchanged in terms of leadership or strategy. Investors will likely monitor the upcoming earnings release for further insight into Twist Bioscience’s financial trajectory.
